research The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications
Alopecia areata severity and treatment response are linked to specific cytokine levels.
Search
for
Sort by
Research
660-690 / 1000+ results
research Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
research Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
The treatment showed significant hair regrowth in alopecia areata patients without side effects.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
research Apremilast is efficacious in refractory alopecia areata
Apremilast helps regrow hair in hard-to-treat alopecia areata.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Efficacy of intralesional betamethasone versus triamcinolone acetonide in the treatment of alopecia areata
Triamcinolone acetonide and betamethasone 1.75 mg/ml are both effective for treating alopecia areata.
research Twice weekly 5 mg betamethasone oral pulse therapy in the treatment of alopecia areata
Twice-weekly 5 mg betamethasone helps hair regrowth in alopecia areata.
research Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Bilateral non-specific orbital inflammation (orbital "pseudotumour"), posterior scleritis, and anterior uveitis associated with hypothyroidism in a child
Intralesional cidofovir might be a viable alternative treatment for certain conditions.
research Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
Belatacept may be a promising treatment for alopecia areata.
research 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Efficacy and Safety of Combination 308-nm Excimer Laser and Intralesional Corticosteroid versus Intralesional Corticosteroid Monotherapy in the Treatment of Frontal Fibrosing Alopecia: A Pilot Study
Combining laser and corticosteroid is not better than corticosteroid alone for treating frontal fibrosing alopecia.
research Hepatitis C ‐related mixed type vitiligo in a patient with I vemark syndrome
A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
research IMMUNOTHERAPY OF CANCER: IMMUNE CHECKPOINT BLOCKERS, VACCINES AND ADOPTIVE T CELL THERAPIES
Enhancing immune response can improve cancer treatment effectiveness.
research Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Sa1389: LESSONS FROM HEPATITIS C TREATMENT DURING THE COVID-19 PANDEMIC: DECREASED RESOURCE UTILIZATION LEADS TO SIMILAR EFFICACY IN BRITISH COLUMBIA, CANADA
Supplemental testosterone may lower liver cancer risk in hepatitis C patients.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Constructing transnational divas: Gendered production of Balkan Turbo-folk music
Switching to a twice-weekly betamethasone treatment led to full hair regrowth in alopecia areata without side effects.
research Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
research 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.